ILD Research
- ALOFT-IPF (IM027-068)
- Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
- Disease group: IPF
- Principal Investigator: Martin Kolb
- Sponsor: Bristol Myers Squibb
- Link: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis – Full Text View – ClinicalTrials.gov
- Status: Active, recruiting
- ALOFT-PPF (IM027-1015)
- Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
- Disease group: PPF
- Principal Investigator: Martin Kolb
- Sponsor: Bristol Myers Squibb
- Link: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis – Full Text View – ClinicalTrials.gov
- Status: Active, recruiting
- AVALYN (AP01-007)
- Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)
- Disease group: PPF
- Principal Investigator: Martin Kolb
- Sponsor: Avalyn Pharma Inc.
- Link: Not yet registered
- Status: Active, recruiting
- BEACON-IPF (PLN-74809-IPF-206)
- Title: A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
- Disease group: IPF
- Principal Investigator: Martin Kolb
- Sponsor: Pliant Therapeutics Inc.
- Link: Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis – Full Text View – ClinicalTrials.gov
- Status: Not yet active
- FIBRONEER-IPF (BI-1305-0014)
- Title: A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Disease group: IPF
- Principal Investigator: Gerard Cox
- Sponsor: Boehringer Ingelheim
- Link: A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) – Full Text View – ClinicalTrials.gov
- Status: Active, not recruiting
- FIBRONEER-PFILD (BI-1305-0023)
- Title: A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
- Disease group: IPF
- Principal Investigator: Gerard Cox
- Sponsor: Boehringer Ingelheim
- Link: A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) – Full Text View – ClinicalTrials.gov
- Status: Active, not recruiting
- IMPALA-2 (SAV006-05)
- Title: A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP)
- Disease group: aPAP
- Principal Investigator: Nathan Hambly
- Sponsor: Savara ApS
- Link: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) – Full Text View – ClinicalTrials.gov
- Status: Active, not recruiting
- TETON-IPF (RINPF-301)
- Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
- Disease group: IPF
- Principal Investigator: Nathan Hambly
- Sponsor: United Therapeutics
- Link: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis – Full Text View – ClinicalTrials.gov
- Status: Active, recruiting
- TETON-PPF (RINPF-305)
- Title: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis
- Disease group: PPF
- Principal Investigator: Nathan Hambly
- Sponsor: United Therapeutics
- Link: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) – Full Text View – ClinicalTrials.gov
- Status: Active, recruiting
- TRANSFORM
- Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Disease group: IPF
- Principal Investigator: Martin Kolb
- Sponsor: GSK
- Link: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) – Full Text View – ClinicalTrials.gov
- Status: Active, recruiting
- Observational Studies/Registries:
- Canadian Registry for Pulmonary Fibrosis (CARE-PF)
- CONNECT ILD
If you are interested in Research, please reach out to Victoria Bryczka at bryczkav@mcmaster.ca